ISRG vs SYRE
Intuitive Surgical vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
ISRG
Intuitive Surgical
60
Buy
VS
SYRE
Spyre Therapeutics, Inc.
67
Buy
| Metric | ISRG | SYRE |
|---|
| AI Score |
60
|
67
|
| Price |
$371.73
|
$93.00
|
| P/E Ratio |
42.21×
|
-54.69×
|
| ROE |
16.0%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
66.7%
|
0.0%
|
| Debt / Equity |
0.00×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
40.0
|
57.5
|
| Beta |
1.46
|
3.026
|
| Expected Upside |
+18.5%
|
—
|
AI Committee View
Current Innellis committee reasoning for ISRG versus SYRE.
SYRE leads by 7 points.
SYRE scores 67/100 (Buy) versus ISRG at 60/100 (Buy).
ISRG Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 17.8% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 45.2 is expensive by classic value standards — Value
- Price-to-book of 11.3x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
SYRE Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical